Biotech Values

[linhdtu]

Vir ,from John at Endpoints :

Vir’s Chief Medical Officer Phillip Pang said that extrapolations from preclinical data on the molecule made the company’s scientists think it would take a much higher dose of VIR-3434 to achieve the intended response—meaning the actual data is even more promising for the drug’s future.

“To have achieved it with a dose of 6 mg is unexpected,” Pang said in a statement. “Coupled with initial data that shows VIR-3434 was well tolerated at up to 3,000 mg in healthy volunteers, I am hopeful that we are seeing just the beginning of VIR-3434’s capabilities.”